TY - JOUR
PY - 2021//
TI - A clinical rationale for assessing the impact of childhood sexual abuse on adjunctive subcutaneous esketamine for treatment-resistant depression
JO - Frontiers in psychiatry
A1 - Magalhães, Eduardo Jorge Muniz
A1 - Sarin, Luciana Maria
A1 - Del Sant, Lorena Catarina
A1 - Lucchese, Ana Cecília
A1 - Nakahira, Carolina
A1 - Tuena, Marco Aurélio
A1 - Puertas, Camila Brito
A1 - Rodovalho Fava, Victor Augusto
A1 - Delfino, Rodrigo Simonini
A1 - Surjan, Juliana
A1 - Steglich, Matheus Souza
A1 - Barbosa, Matheus Ghossain
A1 - Abdo, Guilherme
A1 - Del Porto, José Alberto
A1 - Nemeroff, Charles B.
A1 - Cogo-Moreira, Hugo
A1 - Lacerda, Acioly Luiz Tavares
A1 - Mello, Andrea Feijó
SP - e608499
EP - e608499
VL - 12
IS -
N2 - BACKGROUND: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide, there is a lack of data on the CSA effects on this emerging treatment. Here, we assess the impact of CSA on adjunctive subcutaneous (SC) esketamine for treatment-resistant depression (TRD).
METHODS: A directed acyclic graphic (DAG) was designed to identify clinical confounders between CSA and esketamine predictors of response. The confounders were applied in a statistical model to predict depression symptom trajectory in a sample of 67 TRD outpatients.
RESULTS: The patient sample had a relatively high prevalence rate of CSA (35.82%). Positive family history of first-degree relatives with alcohol use disorder and sex were clinical mediators of the effects of esketamine in a CSA adult population. Overall, the presence of at least one CSA event was unrelated to esketamine symptom reduction.
CONCLUSIONS: Unlike responses to conventional antidepressants and psychotherapy, CSA does not appear to predict poor response to esketamine. Language: en
LA - en
SN - 1664-0640
UR - http://dx.doi.org/10.3389/fpsyt.2021.608499
ID - ref1
ER -